China-based Duality Biotherapeutics' (HKEX:09606) partner, Avenzo Therapeutics, Inc., a California-based clinical-stage biotechnology company developing next-generation oncology therapies, announced on Tuesday that the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical study evaluating AVZO-1418/DB-1418.
AVZO-1418/DB-1418 is a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumours.
On January 7, 2025, DualityBio and Avenzo announced that they had entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture, and commercialise AVZO-1418/DB-1418 globally (excluding Greater China).
The Phase 1/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-1418/DB-1418 as a single agent and in combination therapy in patients with advanced solid tumours.
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Exact Sciences secures Medicare coverage for Oncodetect MRD test in colorectal cancer
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
Celltrion USA launches denosumab biosimilars STOBOCLO and OSENVELT (denosumab-bmwo) in US
HotSpot Therapeutics presents small molecule CBM signalosome inhibitor program data